8-K: Veru Reports Strong Q3, Enobosarm Shows Promising Data

Veru Inc. announced positive fiscal 2025 third-quarter financial results and significant clinical progress for its enobosarm program, highlighting its potential in chronic weight loss management.

Summary

• Reported positive efficacy and safety data from Phase 2b QUALITY study for enobosarm, showing 100% average preservation of total lean mass (p<0.001) and greater fat loss (42% greater with 6mg dose, 12% greater with 3mg dose) when added to semaglutide at 16 weeks.
• Enobosarm 3mg + semaglutide group demonstrated 0% lean mass loss and 100% fat mass loss in total body weight lost, compared to 34% lean mass and 66% fat mass for placebo + semaglutide.
• Enobosarm treatment resulted in a 59.8% relative reduction (p=0.006) in patients experiencing a clinically significant stair climb physical function decline (17% vs 44.8% for placebo) at 16 weeks.
• Reported positive efficacy and safety data from Phase 2b QUALITY Maintenance Extension study, where enobosarm monotherapy significantly reduced body weight regained by 46% after semaglutide discontinuation.
• The placebo group regained 43% of body weight (5.06 lbs) after semaglutide discontinuation, while the 3mg enobosarm group regained 1.41% (2.73 lbs).
• Mean tissue composition of body weight regained was 28% fat and 72% lean mass in the placebo group, versus 0% fat and 100% lean mass in both enobosarm groups.
• Enobosarm monotherapy preserved more than 100% of lean mass (p<0.001 for 3mg, p=0.004 for 6mg) and led to 58% (3mg, p=0.085) to 93% (6mg, p=0.008) greater fat loss by end of study compared to placebo.
• Selected a novel modified release oral enobosarm formulation with patent protection through 2037 for its manufacturing process and expected 2046 for new formulation patents.
• Anticipates FDA feedback to clarify the regulatory pathway for enobosarm to preserve lean mass during chronic weight loss management.
• Net loss decreased to $7.3 million ($0.50 per share) for the fiscal third quarter ended June 30, 2025, from $11.0 million ($0.75 per share) for the same period in 2024.
• Net loss decreased to $24.2 million ($1.65 per share) for the nine months ended June 30, 2025, from $29.3 million ($2.23 per share) for the same period in 2024.

Sentiment

Score: 8

Explanation: The strong positive clinical trial results for enobosarm, demonstrating significant advantages in body composition and physical function for weight loss management, are highly encouraging and represent a major step forward for the company's lead asset. The reduction in net loss also indicates improved financial management. However, the decrease in cash reserves and the explicit mention of future funding needs as a risk temper the overall sentiment, suggesting that while the clinical progress is excellent, financial stability remains a key area to monitor.

Positives

• Enobosarm Phase 2b QUALITY study showed 100% preservation of total lean mass and greater fat loss when added to semaglutide.
• Enobosarm significantly reduced the proportion of patients with a clinically significant decline in physical function (stair climb power) by 59.8%.
• Enobosarm Phase 2b QUALITY Maintenance Extension study demonstrated significant reduction in body weight regain (46% reduction) and prevention of fat regain after semaglutide discontinuation.
• Enobosarm monotherapy preserved 100% lean mass and resulted in greater fat loss by the end of the study compared to placebo.
• Enobosarm showed a positive safety profile with fewer gastrointestinal side effects compared to semaglutide alone, and no evidence of drug-induced liver injury, increased obstructive sleep apnea, increased prostate specific antigen, masculinization in women, or suicidal ideation.
• Selection of a novel modified release oral enobosarm formulation strengthens intellectual property with patent protection through 2037 and expected 2046.
• Operating loss from continuing operations decreased to $7.5 million in Q3 2025 from $10.5 million in Q3 2024.
• Net loss from continuing operations decreased to $7.3 million in Q3 2025 from $10.3 million in Q3 2024.
• Overall net loss decreased to $7.3 million in Q3 2025 from $11.0 million in Q3 2024.
• Selling, general and administrative expenses decreased to $5.0 million in Q3 2025 from $5.8 million in Q3 2024.

Negatives

• Cash, cash equivalents, and restricted cash decreased to $15.0 million as of June 30, 2025, from $24.9 million as of September 30, 2024.
• Research and development expenses increased to $12.7 million for the nine months ended June 30, 2025, from $9.5 million for the same period in 2024.

Risks

• Clinical study results may be unsuccessful or insufficient to meet regulatory standards or warrant continued development.
• Inability to reach agreement with the FDA on study design requirements for planned clinical studies, including the Phase 3 program for enobosarm.
• Potential delays in the timing of and results from clinical trials and studies, including due to inability to enroll sufficient subjects.
• Ability to fund planned clinical development and other operations.
• Timing of any submission to the FDA or other regulatory authority and any determinations made by them.
• Potential for disruptions at the FDA or other government agencies to negatively affect the business.
• Any products, if approved, may not be commercially successful.
• Ability to obtain sufficient financing on acceptable terms when needed to fund development and operations and to continue as a going concern.
• Demand for, market acceptance of, and competition against any products or product candidates.
• New or existing competitors with greater resources and capabilities and new competitive product approvals and/or introductions.
• Changes in regulatory practices or policies or government-driven healthcare reform efforts, including pricing pressures and insurance coverage and reimbursement changes.
• Ability to protect and enforce intellectual property.
• Costs and other effects of litigation, including product liability claims, securities litigation, and disputes with the purchaser of the FC2 business.
• Ability to maintain compliance with Nasdaq Stock Market continued listing requirements, including the minimum bid price.
• Ability to identify, successfully negotiate, and complete suitable acquisitions or other strategic initiatives.
• Ability to successfully integrate acquired businesses, technologies, or products.

Future Outlook

Veru anticipates receiving FDA feedback to clarify the regulatory pathway for enobosarm to preserve lean mass during chronic weight loss management. The company plans to make the novel modified release oral enobosarm formulation available for further clinical studies and commercialization, and expects to present the full data from the Phase 2b QUALITY and Maintenance Extension studies, followed by a planned Phase 3 program for enobosarm as a body composition drug.

Management Comments

• "We have now reported all the positive efficacy and safety topline results from our Phase 2b QUALITY and Maintenance Extension study, and are looking forward to FDA feedback on the regulatory pathway for enobosarm to be used as an adjunctive therapy with GLP-1 RA to preserve lean mass while burning more fat for chronic weight loss management."
• "The efficacy and safety of Veru's oral agent enobosarm looks better than any of the injectable myostatin inhibitors now under development by our competitors."
• "Unlike our competitors, enobosarm has positive physical function data measured by stair climb power."
• "Furthermore, we have strengthened our intellectual property position with the selection of a novel modified release oral enobosarm formulation confirmed in a clinical pharmacokinetic study."

Industry Context

The announcement positions enobosarm as a potentially superior oral alternative to injectable myostatin inhibitors currently under development by competitors, particularly due to its demonstrated positive physical function data. It also highlights enobosarm's ability to enhance the benefits of GLP-1 RA drugs like semaglutide by making weight loss more selective for fat and preserving lean mass, addressing a key unmet need in chronic weight management.

Comparison to Industry Standards

• Enobosarm's efficacy and safety profile is stated to be "better than any of the injectable myostatin inhibitors now under development by competitors."
• Unlike competitors, enobosarm has demonstrated positive physical function data measured by stair climb power.
• The combination of enobosarm and semaglutide resulted in 0% lean mass loss and 100% fat mass loss in total body weight lost, a significant improvement over semaglutide alone (34% lean mass and 66% fat mass loss).
• Enobosarm significantly reduced body weight regain by 46% and prevented fat regain after semaglutide discontinuation, with regained weight being 100% lean mass compared to 28% fat and 72% lean mass in the placebo group.
• The combination therapy showed fewer gastrointestinal side effects compared to semaglutide alone.

Legal Proceedings

• Costs and other effects of litigation, including product liability claims.
• Securities litigation.
• Litigation and other disputes with the purchaser of the Company’s FC2 business.

Stakeholder Impact

• Shareholders: Positive clinical data could lead to increased valuation and future revenue potential, but ongoing cash burn and the need for future financing pose risks.
• Patients: Potential for a novel, more effective, and safer adjunctive therapy for chronic weight loss management that preserves muscle and physical function.
• Employees: Continued focus on clinical development and potential for future commercialization.
• Creditors: Financial performance and future funding needs will be closely monitored.

Next Steps

• Anticipate FDA feedback to clarify the regulatory pathway for enobosarm.
• Host a conference call and webcast on August 12, 2025, to discuss results.
• Plan for further clinical studies and commercialization of the novel modified release oral enobosarm formulation.
• Plan for a Phase 3 program for enobosarm as a body composition drug.

Key Dates

Recommendation

The compelling positive efficacy and safety data from the Phase 2b QUALITY and Maintenance Extension studies for enobosarm represent a significant de-risking event for Veru's lead clinical asset. The drug's ability to preserve lean mass, enhance fat loss, improve physical function, and reduce side effects when combined with GLP-1 RAs, and its effectiveness in preventing weight regain post-GLP-1 discontinuation, positions it uniquely in a rapidly growing and high-demand market. While the company faces ongoing cash burn and the need for future financing to advance to Phase 3 and commercialization, the strong clinical profile and intellectual property protection suggest substantial long-term value creation potential, making it an attractive 'buy' for investors with a medium to long-term horizon who are comfortable with biopharmaceutical development risks.

Keywords

Veru Inc., VERU, Biopharmaceutical, Cardiometabolic diseases, Inflammatory diseases, Enobosarm, GLP-1 RA, Weight loss management, Muscle preservation, Fat loss, Clinical trials, Phase 2b QUALITY study, Maintenance Extension study, Drug development, SEC filing, Financial results, Q3 2025, Pharmacokinetics, Modified release formulation, Intellectual property, FDA regulatory pathway, Sabizabulin